InsiderTrades.com logo
Bihua Chen net worth and biography
  • LinkedIn

Bihua Chen Biography and Net Worth

Director of BlossomHill Therapeutics

Bihua Chen founded Cormorant Asset Management, LP (“Cormorant”), an investment firm focused on innovative biotech, MedTech and life science companies with more than $3 billion under management. Ms. Chen manages Cormorant’s public fund as well as its private funds. Prior to founding Cormorant, Ms. Chen managed a separate account focused on the healthcare sector as a subadviser to a large, multi-strategy hedge fund based in New York. Ms. Chen obtained a Master of Business Administration from the Wharton School of Business and a Master of Science in molecular biology from the Weill Cornell Graduate School of Medical Sciences. Ms. Chen also holds a Bachelor of Science in genetics and genetic engineering from Fudan University, Shanghai, China.

What is Bihua Chen's net worth?

The estimated net worth of Bihua Chen is at least $58.26 million as of August 10th, 2026. Ms. Chen owns 3,614,034 shares of BlossomHill Therapeutics stock worth more than $58,258,228 as of August 21st. This net worth estimate does not reflect any other investments that Ms. Chen may own. Learn More about Bihua Chen's net worth.

How do I contact Bihua Chen?

The corporate mailing address for Ms. Chen and other BlossomHill Therapeutics executives is , ,. Learn More on Bihua Chen's contact information.

Has Bihua Chen been buying or selling shares of BlossomHill Therapeutics?

Within the last three months, Bihua Chen has bought $5,000,000.00 of BlossomHill Therapeutics stock. Most recently, on Monday, August 10th, Bihua Chen bought 312,500 shares of BlossomHill Therapeutics stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the completion of the transaction, the director now directly owns 3,614,034 shares of the company's stock, valued at $57,824,544. Learn More on Bihua Chen's trading history.

Are insiders buying or selling shares of BlossomHill Therapeutics?

In the last year, BlossomHill Therapeutics insiders bought shares 7 times. They purchased a total of 1,573,900 shares worth more than $25,181,900.00. The most recent insider tranaction occured on August, 10th when Director John P Schmid bought 6,000 shares worth more than $96,000.00. Learn More about insider trades at BlossomHill Therapeutics.

Information on this page was last updated on 8/10/2026.

Bihua Chen Insider Trading History at BlossomHill Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2026Buy312,500$16.00$5,000,000.003,614,034View SEC Filing Icon  
See Full Table

Bihua Chen Buying and Selling Activity at BlossomHill Therapeutics

This chart shows Bihua Chen's buying and selling at BlossomHill Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BlossomHill Therapeutics Company Overview

BlossomHill Therapeutics logo
BlossomHill Therapeutics Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $16.11
Low: $15.75
High: $16.50

50 Day Range

MA: N/A

2 Week Range

Now: $16.11
Low: $15.25
High: $17.25

Volume

39,232 shs

Average Volume

286,258 shs

Market Capitalization

$493.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A